Gater, Adam
Reaney, Matthew
Findley, Amy
Brun-Strang, Catherine
Burrows, Kate
Nguyên-Pascal, My-Liên
Roborel de Climens, Aude http://orcid.org/0000-0002-5065-2010
Clinical trials referenced in this document:
Documents that mention this clinical trial
Development and First Use of the Patient’s Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies
https://doi.org/10.1007/s40264-019-00877-4
Funding for this research was provided by:
Sanofi
Article History
First Online: 2 November 2019
Compliance with Ethical Standards
:
: Adam Gater, Amy Findley, and Kate Burrows are employed by Adelphi Values, which has received funding from Sanofi to analyse data reported in this paper. Aude Roborel de Climens, My-Liên Nguyên-Pascal, and Catherine Brun-Strang are paid employees of Sanofi. Aude Roborel de Climens and My-Liên Nguyên-Pascal are stockholders of Sanofi. Matthew Reaney was a paid employee and stockholder of Sanofi at the time of this study.
: The DRI13940 study protocol and subsequent substantial amendments were approved by local independent ethics committees and the competent regulatory authority in each country for each investigational site. The study was registered with EudraCT (2016-001328-77) and ClinicalTrials.gov (NCT02973321), and conducted according to Good Clinical Practice guidelines, any local guidelines, the Declaration of Helsinki, and European Directive. The study did not include any procedures performed on animals. Written informed consent was obtained from all individual participants included in the study.